Daniel N A Ankrah1,2, Delese M Darko3, George Sabblah3, Aukje Mantel-Teeuwisse2, Hubert M G Leufkens2,4. 1. a Department of Pharmacy , Korle-Bu Teaching Hospital , Korle-Bu, Accra , Ghana. 2. b Division of Pharmacoepidemiology & Clinical Pharmacology , Utrecht Institute for Pharmaceutical Sciences (UIPS) , Utrecht , the Netherlands. 3. c Food and Drugs Authority , Cantonments-Accra , Ghana. 4. d Medicines Evaluation Board , Utrecht , the Netherlands.
Abstract
BACKGROUND: Timely reporting of safety information post vaccination is pivotal for the success of any vaccination program. Reports of adverse events following immunization (AEFI) of 6 different vaccinations from Ghana were analysed for signals. METHODS: De-identified data from active surveillance for AEFIs after 2009 AH1N1 influenza, yellow fever, meningitis, measles-rubella, pneumococcal-rotavirus and human papilloma virus vaccinations were used. All vaccinations occurred between January 2010 and December 2013. The ten most occurring events for each vaccination were captured and arranged using Medical Dictionary for Regulatory Authorities (MedDRA) Preferred Term (PT) and System Organ Classification (SOC) codes. Adverse event incidence rates were calculated for each vaccine type, and signals were generated using proportional reporting ratios (PRR). RESULTS: A total number of 5,141 reports were analysed ranging from 33 (human papilloma virus) to 1958 (measles-rubella). Between 22% and 55% of all AEFIs per vaccine type were collected on the day of vaccination. For each vaccine type, at least 87% of all reported AEFIs occurred in the first 7 days post-vaccination. Multiple reports were received per vaccine type. For the MR vaccine, urticarial recorded the highest attack rate of 6.6 (95% CI 6.2, 7.1) per 100,000 vaccines. The AEFI with the highest PRR for both human papilloma and measles-rubella vaccines was abdominal pain, recording a PRR of 8.15 (95% CI 3.46, 19.23) and 43.75 (95% CI 17.81, 107.45) respectively. CONCLUSION: These results underscore the competency of public health systems in sub-Saharan African countries (like Ghana) to identify most frequently occurring and important vaccine related safety issues.
BACKGROUND: Timely reporting of safety information post vaccination is pivotal for the success of any vaccination program. Reports of adverse events following immunization (AEFI) of 6 different vaccinations from Ghana were analysed for signals. METHODS: De-identified data from active surveillance for AEFIs after 2009 AH1N1 influenza, yellow fever, meningitis, measles-rubella, pneumococcal-rotavirus and humanpapilloma virus vaccinations were used. All vaccinations occurred between January 2010 and December 2013. The ten most occurring events for each vaccination were captured and arranged using Medical Dictionary for Regulatory Authorities (MedDRA) Preferred Term (PT) and System Organ Classification (SOC) codes. Adverse event incidence rates were calculated for each vaccine type, and signals were generated using proportional reporting ratios (PRR). RESULTS: A total number of 5,141 reports were analysed ranging from 33 (human papilloma virus) to 1958 (measles-rubella). Between 22% and 55% of all AEFIs per vaccine type were collected on the day of vaccination. For each vaccine type, at least 87% of all reported AEFIs occurred in the first 7 days post-vaccination. Multiple reports were received per vaccine type. For the MR vaccine, urticarial recorded the highest attack rate of 6.6 (95% CI 6.2, 7.1) per 100,000 vaccines. The AEFI with the highest PRR for both humanpapilloma and measles-rubella vaccines was abdominal pain, recording a PRR of 8.15 (95% CI 3.46, 19.23) and 43.75 (95% CI 17.81, 107.45) respectively. CONCLUSION: These results underscore the competency of public health systems in sub-Saharan African countries (like Ghana) to identify most frequently occurring and important vaccine related safety issues.
Entities:
Keywords:
Ghana; active surveillance; immunization; proportional reporting ratio; safety
Authors: Glenda Lawrence; Robert Menzies; Margaret Burgess; Peter McIntyre; Nicholas Wood; Ian Boyd; Patrick Purcell; David Isaacs Journal: Commun Dis Intell Q Rep Date: 2003
Authors: Hugo Razuri; Candice Romero; Yeny Tinoco; Maria Claudia Guezala; Ernesto Ortiz; Maria Silva; Erik Reaves; Maya Williams; Victor Alberto Laguna-Torres; Eric S Halsey; Jorge Gomez; Eduardo Azziz-Baumgartner; Marc-Alain Widdowson; Joe Bresee; Ann Moen; Timothy M Uyeki; Andrew Bennett; Joel M Montgomery; Daniel G Bausch Journal: Bull World Health Organ Date: 2012-04-01 Impact factor: 9.408
Authors: Jan Bonhoeffer; Adwoa Bentsi-Enchill; Robert T Chen; Margaret C Fisher; Michael S Gold; Katharina Hartman; Ulrich Heininger; Bernard Hoet; Thomas Jefferson; Najwa Khuri-Bulos; Katrin Kohl; S Michael Marcy; David Nalin; Robert Pless; Hernan Sanabria-Rojas; Karen Sleeman; Robert Wise Journal: Vaccine Date: 2008-12-04 Impact factor: 3.641
Authors: A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas Journal: Eur J Clin Pharmacol Date: 1998-06 Impact factor: 2.953
Authors: Claude-Roger Ouandaogo; Téné M Yaméogo; Fabien V K Diomandé; Charles Sawadogo; Bassirou Ouédraogo; Rasmata Ouédraogo-Traoré; Lorenzo Pezzoli; Mamoudou H Djingarey; Nehémie Mbakuliyemo; Patrick L F Zuber Journal: Vaccine Date: 2012-01-09 Impact factor: 3.641
Authors: Daniel N A Ankrah; Aukje K Mantel-Teeuwisse; Marie L De Bruin; Philip K Amoo; Charles N Ofei-Palm; Irene Agyepong; Hubert G M Leufkens Journal: Drug Saf Date: 2013-04 Impact factor: 5.606
Authors: J-P Guthmann; F de La Rocque; M Boucherat; D van Cauteren; L Fonteneau; A Lécuyer; R Cohen; D Lévy-Bruhl Journal: Arch Pediatr Date: 2009-03-21 Impact factor: 1.180
Authors: Dan K Kajungu; Annette Erhart; Ambrose Otau Talisuna; Quique Bassat; Corine Karema; Carolyn Nabasumba; Michael Nambozi; Halidou Tinto; Peter Kremsner; Martin Meremikwu; Umberto D'Alessandro; Niko Speybroeck Journal: PLoS One Date: 2014-05-01 Impact factor: 3.240